Cargando…
Medical treatment for urogenital tuberculosis (UGTB)
Urogenital tuberculosis (UGTB) should in general be treated as pulmonary TB with a four-drug regimen of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide for a total of 6 months, Ethambutol and Pyrazinamide only the first two months. Some patients may need longer treatment (cavitary disease, kidney...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
German Medical Science GMS Publishing House
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301712/ https://www.ncbi.nlm.nih.gov/pubmed/30671335 http://dx.doi.org/10.3205/id000039 |
_version_ | 1783381848916754432 |
---|---|
author | Wejse, Christian |
author_facet | Wejse, Christian |
author_sort | Wejse, Christian |
collection | PubMed |
description | Urogenital tuberculosis (UGTB) should in general be treated as pulmonary TB with a four-drug regimen of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide for a total of 6 months, Ethambutol and Pyrazinamide only the first two months. Some patients may need longer treatment (cavitary disease, kidney abscess/malfunction, HIV co-infection). Treatment of multi-drug resistant tuberculosis (MDR-TB) requires use of long-term intravenous treatment with aminoglycosides and other drugs with considerable toxicity for 18–24 months. Complications such as urinary tract obstruction may occur and should be treated with corticosteroids or surgery. |
format | Online Article Text |
id | pubmed-6301712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | German Medical Science GMS Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-63017122019-01-22 Medical treatment for urogenital tuberculosis (UGTB) Wejse, Christian GMS Infect Dis Article Urogenital tuberculosis (UGTB) should in general be treated as pulmonary TB with a four-drug regimen of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide for a total of 6 months, Ethambutol and Pyrazinamide only the first two months. Some patients may need longer treatment (cavitary disease, kidney abscess/malfunction, HIV co-infection). Treatment of multi-drug resistant tuberculosis (MDR-TB) requires use of long-term intravenous treatment with aminoglycosides and other drugs with considerable toxicity for 18–24 months. Complications such as urinary tract obstruction may occur and should be treated with corticosteroids or surgery. German Medical Science GMS Publishing House 2018-08-09 /pmc/articles/PMC6301712/ /pubmed/30671335 http://dx.doi.org/10.3205/id000039 Text en Copyright © 2018 Wejse This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Wejse, Christian Medical treatment for urogenital tuberculosis (UGTB) |
title | Medical treatment for urogenital tuberculosis (UGTB) |
title_full | Medical treatment for urogenital tuberculosis (UGTB) |
title_fullStr | Medical treatment for urogenital tuberculosis (UGTB) |
title_full_unstemmed | Medical treatment for urogenital tuberculosis (UGTB) |
title_short | Medical treatment for urogenital tuberculosis (UGTB) |
title_sort | medical treatment for urogenital tuberculosis (ugtb) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301712/ https://www.ncbi.nlm.nih.gov/pubmed/30671335 http://dx.doi.org/10.3205/id000039 |
work_keys_str_mv | AT wejsechristian medicaltreatmentforurogenitaltuberculosisugtb |